Select Language
IGF-I R
IGF-I R Overview
| English Name | Insulin-like growth factor I receptor | Approved Drugs | 7 |
| Drugs in Clinical Trials | 24 | Target Synonym | IGF-I receptor，IGF1R，Insulin Like Growth Factor 1 Receptor，Insulin-Like Growth Factor 1 Receptor，Insulin-Like Growth Factor I Receptor，Soluble IGF1R Variant 1，Soluble IGF1R Variant 2，CD221 Antigen，CD221，IGFIR，JTK13，IGFR，Receptor， IGF Type 1，MGC18216 |
| Highest Development Stage | Approved | ||
| English Name | Insulin-like growth factor I receptor |
| Target Synonym | IGF-I receptor，IGF1R，Insulin Like Growth Factor 1 Receptor，Insulin-Like Growth Factor 1 Receptor，Insulin-Like Growth Factor I Receptor，Soluble IGF1R Variant 1，Soluble IGF1R Variant 2，CD221 Antigen，CD221，IGFIR，JTK13，IGFR，Receptor， IGF Type 1，MGC18216 |
| Approved Drugs | 7 |
| Drugs in Clinical Trials | 24 |
| Highest Development Stage | Approved |
IGF-I R Product List
- Product Category
Cell (2)
- Product Status
Launched (2)
- Species
Human (2)
- Tag
- (2)
- Conjugate
- (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT CHEK-ATF107 |  Human | HEK293 | Human IGF-1 R (Luc) HEK293 Reporter Cell |  |  Add to Cart | ||
CNIH-ATP102 | Human | NIH-3T3 | NIH-3T3/Human IGF-1 R Stable Cell Line Development Service | | Add to Cart |
Total: 2
- 1
IGF-I R Synonyms
IGF1R,IGFR,JTK13,CD221,MGC142170,MGC142172,MGC18216
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Veligrotug | VRDN-001; ZB-001; AVE-1642 | Phase 3 Clinical | Viridian Therapeutics Inc | Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms | Details |
| VRDN-003 | VRDN-003 | Phase 3 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
| Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lymphoma; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Sarcoma; Prostatic Neoplasms; Solid tumours; Sarcoma, Ewing; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Intestinal Neoplasms; Bone metastases; Rhabdomyosarcoma | Details |
| Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Multiple Myeloma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Mouth Neoplasms; Lip Neoplasms; Eye Diseases; Orbital Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Carcinoma, Basosquamous; Prostatic Neoplasms; Sarcoma, Ewing; Breast Neoplasms; Adrenocortical Carcinoma; Liver Neoplasms; Graves Ophthalmopathy; Endocrine System Diseases; Hormone-Resistant Prostate Neoplasms; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Chondrosarcoma; Thyroid Diseases; Solid tumours; Carney Complex | Details |
| FPI-1434 | [225Ac]-FPI-1434; FPX-01 | Phase 2 Clinical | Fusion Pharma | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
| Dalotuzumab | h7C-10; MK-0646; F-50-035 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
| CT-102 | CT-102 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| Mecasermin Rinfabate | rhIGF-I/rhIGFBP-3; TAK-607; OHB-607; IGF-I/IGFBP-3; SHP-607; HGT-ROP-001 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Lung Diseases; Myotonic Dystrophy; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Laron Syndrome | Details |
| Insulin growth factor receptor type 1 antisense therapy (Imvax) | IGV-001 | Phase 2 Clinical | Thomas Jefferson University | Glioblastoma | Details |
| MHB018A | MHB 018A; MHB-018A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Graves Ophthalmopathy | Details |
| PHP-1003 | PHP-1003; PHP1003 | Phase 2 Clinical | Suzhou Pulekang Pharmaceutical Technology Co Ltd | Graves Ophthalmopathy | Details |
| Lonigutamab | VB-421 | Phase 2 Clinical | Pierre Fabre Group | Graves Ophthalmopathy | Details |
| Cixutumumab | A-12; IMC-A12; LY-3012217; NSC-742460 | Phase 2 Clinical | Eli Lilly And Company | Chondrosarcoma, Extraskeletal Myxoid; Pinealoma; Brain Stem Neoplasms; Gliosarcoma; Breast Neoplasms; Gastrinoma; Medullary thyroid cancer (MTC); Lymphoma, Mantle-Cell; Neuroblastoma; Adenocarcinoma, Bronchiolo-Alveolar; Osteosarcoma; Retinoblastoma; Neurofibrosarcoma; Sarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Glucagonoma; Mesothelioma; Glioma; Adenocarcinoma; Melanoma; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Esophageal adenocarcinoma; Sarcoma, Alveolar Soft Part; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Metastatic breast cancer; Colorectal Neoplasms; Hepatoblastoma; Stomach Neoplasms; Mesenchymoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Esophageal Neoplasms; Insulinoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Desmoplastic Small Round Cell Tumor; Hema | Details |
| Picropodophyllin | AXL-1717; NSC-36407; PPP | Phase 2 Clinical | Axelar Ab | Ependymoma; Papillomavirus Infections; Glioblastoma; Oligodendroglioma; Astrocytoma; Gliosarcoma; Carcinoma, Non-Small-Cell Lung | Details |
| NNC0268-0965 | NNC0268-0965 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
| IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
| Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Healthy Aging; Burns; Sunburn | Details | |
| SAR-446159 | SAR-446159; ABL-301 | Phase 1 Clinical | Abl Bio Inc | Parkinson Disease | Details |
| VRDN-002 | VRDN-002 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
| LX-101 (Lirum Therapeutics) | 765IGF-MTX; IGF/MTX | Phase 1 Clinical | Lirum Therapeutics Inc | Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Graves Ophthalmopathy; Brain Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Gastrointestinal Neoplasms; Melanoma | Details |
| ZB-011 | ZB-011; ZB011 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
| Teprotumumab biosimilar(Boxiao Bio-pharma) | Phase 1 Clinical | Zhejiang Boxiao Bio-pharmaceutical Co Ltd | Graves Ophthalmopathy | Details | |
| 124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
| ALTSuLIN | Clinical | Diabetes Mellitus, Type 1; Laron Syndrome | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Growth hormone deficiency; Diabetes Mellitus, Lipoatrophic; Dwarfism | null | 1994-10-05 | Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; HIV-Associated Lipodystrophy Syndrome; Dwarfism; Growth hormone deficiency | Details | |
| Mecasermin (Ipsen) | FK-780; IGF-1; MKN-031; rhIGF-I (Ipsen) | Approved | Genentech Inc | Increlex | United States | Failure to Thrive | Ipsen Inc | 2005-08-30 | Failure to Thrive; Autism Spectrum Disorder; Phelan-McDermid syndrome; X-Linked Combined Immunodeficiency Diseases; Growth Disorders; Laron Syndrome | Details |
| Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Neuroma, Acoustic; Meningioma | Details |
| IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
| Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Hepatic Insufficiency; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Thyroid Neoplasms; Hematologic Neoplasms; Colorectal Neoplasms; Cholangiocarcinoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Thyroid Carcinoma, Anaplastic; Stomach Neoplasms | Details |
| Teprotumumab biosimilar (Innovent Biologics) | IBI-311 | Approved | Innovent Biologics(Suzhou) Co Ltd | 信必敏 | Mainland China | Graves Ophthalmopathy | Innovent Biologics(Suzhou) Co Ltd | 2025-03-11 | Graves Ophthalmopathy | Details |
| Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001; RV-001（River Vision） | Approved | Genmab A/S, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Sarcoma; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland